Fused heterocyclic compounds

1. A compound having the formula:

wherein

A and B independently are CR′, wherein each R′ is independently selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, arylalkyl, —C(O)R 7 , —CO 2 R 8 and —C(O)NR 5 R 6 ;

V is either a bond and W is —N(R″)—, or V is —N(R″)— and W is a bond, wherein R″ is hydrogen or (C 1 -C 5 )alkyl;

Z is —N(R)—CH 2 —, wherein R is selected from the group consisting of hydrogen, (C 1 -C 7 )alkyl, heterocycloalkyl(C 1 -C 7 )alkyl, aryl, arylalkyl, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —S(O) m NR 5 R 6 and —S(O) m R 7 ;

each R 1 is independently selected from the group consisting of halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen, —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 9 is selected from the group consisting of alkyl, aryl and aryl(C 1 -C 5 )alkyl;

the subscript m is an integer from 1 to 2;

the subscript n is an integer from 1 to 4; and

wherein

 is a substituted benzene ring;

with the proviso that R 2 is not hydrogen when A and B are both CH, V is a bond, and W is —N(R″)—.

2. The compound of claim 1 , wherein V is —N(R″)—.

3. The compound of claim 1 , wherein W is —N(R″)—.

4. The compound of claim 1 , wherein W is —NH—.

5. The compound of claim 1 , wherein R is (C 1 -C 7 )alkyl or heterocycloalkyl(C 1 -C 7 )alkyl.

6. The compound of claim 1 , wherein R 2 is (C 1 -C 5 )alkyl or aryl.

7. A compound having the formula:

wherein

A and B independently are CR′, wherein each R′ is independently selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, arylalkyl, —C(O)R 7 , —CO 2 R 8 and —C(O)NR 5 R 6 ;

Z is —N(R)—CH 2 —, wherein R is heterocycloalkyl(C 1 -C 7 )alkyl;

R″ is hydrogen or (C 1 -C 5 )alkyl;

each R 1 is independently selected from the group consisting of hydrogen, halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen, —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 9 is selected from the group consisting of alkyl, aryl and aryl(C 1 -C 5 )alkyl;

the subscript m is an integer from 1 to 2; and

the subscript n is an integer from 0 to 4;

with the proviso that R 2 is not hydrogen when A and B are both CH.

8. The compound of claim 7 , wherein R 2 is (C 1 -C 5 )alkyl or aryl.

9. The compound of claim 1 , having the formula:

wherein

V is either a bond and W is —N(R″)—, or V is —N(R″)— and W is a bond, wherein R″ is hydrogen or (C 1 -C 5 )alkyl;

R is selected from the group consisting of hydrogen, (C 1 -C 7 )alkyl, heterocycloalkyl(C 1 -C 7 )alkyl, aryl, arylalkyl, —C(O)R 7 , CO 2 R 8 , —C(O)NR 5 R 6 , —S(O) m NR 5 R 6 and —S(O) m R 7 ;

each R 1 is independently selected from the group consisting of halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen, —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 9 is selected from the group consisting of alkyl, aryl and aryl(C 1 -C 5 )alkyl;

the subscript m is an integer from 1 to 2; and

the subscript n is an integer from 1 to 4;

with the proviso that R 2 is not hydrogen when V is a bond and W is —N(R″)—.

10. The compound of claim 9 , wherein V is a bond and W is —N(R″)—.

11. The compound of claim 10 or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is selected from the group consisting of:

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound having the formula:

wherein

A and B independently are CR′, wherein R′ is independently selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, arylalkyl, —C(O)R 7 , —CO 2 R 8 and —C(O)NR 5 R 6 ;

V is either a bond and W is —N(R″)—, or V is —N(R″)— and W is a bond, wherein R″ is hydrogen or (C 1 -C 5 )alkyl;

Z is —N(R)—CH 2 —, wherein R is selected from the group consisting of hydrogen, (C 1 -C 7 )alkyl, heterocycloalkyl(C 1 -C 7 )alkyl, aryl, arylalkyl, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —S(O) m NR 5 R 6 and —S(O) m R 7 ;

each R 1 is independently selected from the group consisting of hydrogen, halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, arylalkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen, —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl;

R 9 is selected from the group consisting of alkyl, aryl and arylalkyl;

the subscript m is an integer from 1 to 2;

the subscript n is an integer from 0 to 4; and

 is a benzene ring;

with the proviso that R 2 is not hydrogen when A and B are both CH, V is a bond, and W is —N(R″)—.

13. A method for treating a condition or disorder selected from the group consisting of obesity, an eating disorder, an anxiety disorder and a mood disorder, comprising

administering to a subject in need thereof a therapeutically effective amount of a compound having the formula:

wherein

A and B independently are CR′, wherein R′ is independently selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, arylalkyl, —C(O)R 7 , —CO 2 R 8 and —C(O)NR 5 R 6 ;

V is either a bond and W is —N(R″)—, or V is —N(R″)— and W is a bond, wherein R″ is hydrogen or (C 1 -C 5 )alkyl;

Z is —N(R)—CH 2 —, wherein R is selected from the group consisting of hydrogen, (C 1 -C 7 )alkyl, heterocycloalkyl(C 1 -C 7 )alkyl, aryl, arylalkyl, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —S(O) m NR 5 R 6 and —S(O) m R 7 ;

each R 1 is independently selected from the group consisting of hydrogen, halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, arylalkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen, —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl;

R 9 is selected from the group consisting of alkyl, aryl and arylalkyl;

the subscript m is an integer from 1 to 2;

the subscript n is an integer from 0 to 4; and

 is a benzene ring;

with the proviso that R 2 is not hydrogen when A and B are both CH, V is a bond, and W is —N(R″)—.

14. The method of claim 13 wherein said compound modulates melanin-concentrating hormone receptor (“MCHR”).

15. The method of claim 13 wherein said compound is administered orally.

16. The method of claim 13 wherein said compound is administered parenterally.

17. A method for modifying eating behavior, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the formula:

wherein

A and B independently are CR′, wherein R′ is independently selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, arylalkyl, —C(O)R 7 , —CO 2 R 8 and —C(O)NR 5 R 6 ;

V is either a bond and W is —N(R″)—, or V is —N(R″)— and W is a bond, wherein R″ is hydrogen or (C 1 -C 5 )alkyl;

Z is —N(R)—CH 2 —, wherein R is selected from the group consisting of hydrogen, (C 1 -C 7 )alkyl, heterocycloalkyl(C 1 -C 7 )alkyl, aryl, arylalkyl, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —S(O) m NR 5 R 6 and —S(O) m R 7 ;

each R 1 is independently selected from the group consisting of hydrogen, halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, arylalkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen, —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl;

R 9 is selected from the group consisting of alkyl, aryl and arylalkyl;

the subscript m is an integer from 1 to 2;

the subscript n is an integer from 0 to 4; and

 is a benzene ring;

with the proviso that R 2 is not hydrogen when A and B are both CH, V is a bond, and W is —N(R″)—.

18. The method of claim 17 , wherein food intake is decreased.

19. The method of claim 17 , wherein food intake is increased.

20. The method of claim 13 , wherein said eating disorder is anorexia nervosa.

21. The method of claim 13 , wherein said anxiety disorder is selected from the group consisting of anxiety, panic disorder and obsessive-compulsive disorder.

22. The method of claim 13 , wherein said mood disorder is depression.

23. A method for modulating melanin-concentrating hormone receptor (“MCHR”), comprising

contacting a cell with a compound having the formula:

wherein

A and B independently are CR′, wherein R′ is independently selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, arylalkyl, —C(O)R 7 , —CO 2 R 8 and —C(O)NR 5 R 6 ;

V is either a bond and W is —N(R″)—, or V is —N(R″)— and W is a bond, wherein R″ is hydrogen or (C 1 -C 5 )alkyl;

Z is —N(R)—CH 2 —, wherein R is selected from the group consisting of hydrogen, (C 1 -C 7 )alkyl, heterocycloalkyl(C 1 -C 7 )alkyl, aryl, arylalkyl, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —S(O) m NR 5 R 6 and —S(O) m R 7 ;

each R 1 is independently selected from the group consisting of hydrogen, halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, arylalkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen, —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl;

R 9 is selected from the group consisting of alkyl, aryl and arylalkyl;

the subscript m is an integer from 1 to 2;

the subscript n is an integer from 0 to 4; and

 is a benzene ring;

with the proviso that R 2 is not hydrogen when A and B are both CH, V is a bond, and W is —N(R″)—.

24. The method of claim 23 , wherein said compound is an MCHR antagonist.

25. The method of claim 23 , wherein said compound is an MCHR agonist.

26. The compound of claim 10 , having the formula:

wherein

R is selected from the group consisting of hydrogen, (C 1 -C 7 )alkyl, heterocycloalkyl(C 1 -C 7 )alkyl, aryl, arylalkyl, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —S(O) m NR 5 R 6 and —S(O) m R 7 ;

each R 1 is independently selected from the group consisting of halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, —OR′″, ═O, —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 4 is selected from the group consisting of hydrogen —OR′″, —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —CN, (C 1 -C 5 )alkyl and aryl, wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl or combined to form a 4-, 5-, 6-, 7- or 8-membered ring containing from one to three atoms selected from the group consisting of O, N, S, and Si;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, aryl and aryl(C 1 -C 5 )alkyl;

R 9 is selected from the group consisting of alkyl, aryl and aryl(C 1 -C 5 )alkyl;

the subscript m is an integer from 1 to 2; and

the subscript n is an integer from 1 to 4;

with the proviso that R 2 is not hydrogen.

27. A compound as in claim 1 , in which the compound is a pharmaceutically acceptable salt.

28. A compound as in claim 1 , in which the compound is a solvate or hydrate.

29. A compound as in claim 1 , in which the compound is in a prodrug form.

30. A compound as in claim 7 , in which the compound is a pharmaceutically acceptable salt.

31. A compound as in claim 7 , in which the compound is a solvate or hydrate.

32. A compound as in claim 7 , in which the compound is in a prodrug form.

33. The pharmaceutical composition of Claim 12 , wherein the compound is a pharmaceutically acceptable salt.

34. The pharmaceutical composition of claim 12 , wherein the compound is a solvate or hydrate.

35. The pharmaceutical composition of claim 12 , where the compound is in a prodrug form.

36. The composition of claim 12 , wherein

of said compound is a substituted benzene ring, said subscript n is an integer from 1 to 4, and each R 1 is independently selected from the group consisting of halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —C(O) 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , where in R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl.

37. The composition of claim 12 , wherein R of said compound is (C 1 -C 7 )alkyl or heterocycloalkyl(C 1 -C 7 )alkyl.

38. The composition of claim 12 , wherein said compound is selected from the group consisting of:

and salts thereof.

39. The method of claim 13 , wherein said condition or disorder is obesity.

40. The method of claim 13 , wherein said condition or disorder is an eating disorder.

41. The method of claim 13 , wherein said condition or disorder is an anxiety disorder.

42. The method of claim 13 , wherein said condition or disorder is a mood disorder.

43. The method of claim 13 , wherein said subject is a human.

44. The method of claim 13 , wherein

of said compound is a substituted benzene ring, said subscript n is an integer from 1 to 4, and each R 1 is independently selected from the group consisting of halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl.

45. The method of claim 17 , wherein

of said compound is a substituted benzene ring, said subscript n is an integer from 1 to 4, and each R 1 is independently selected from the group consisting of halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl.

46. The method of claim 23 , wherein

of said compound is a substituted benzene ring, said subscript n is an integer from 1 to 4, and each R 1 is independently selected from the group consisting of halogen, (C 1 -C 5 )alkyl, perfluoro(C 1 -C 5 )alkyl, —OR′″, —SR′″, aryl, aryl(C 1 -C 5 )alkyl, —NO 2 , —NR 5 R 6 , —C(O)R 7 , —CO 2 R 8 , —C(O)NR 5 R 6 , —N(R 5 )C(O)R 7 , —N(R 5 )CO 2 R 9 , —N(R 7 )C(O)NR 5 R 6 , —S(O) m NR 5 R 6 , —S(O) m R 7 , —CN and —N(R 5 )S(O) m R 9 , wherein R′″ is selected from the group consisting of hydrogen, (C 1 -C 5 )alkyl, aryl and aryl(C 1 -C 5 )alkyl.

47. The method of claim 13 , wherein said compound is selected from the group consisting of:

and salts thereof.